Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445809 · ClinicalTrials.gov registry record
Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury
A clinical trial, sponsored by Abbott RDx Cardiometabolic.
- Completed
- Registry status
- 355
- Enrollment target
NCT00445809: Completed study, sponsored by Abbott RDx Cardiometabolic.
NCT00445809 is a clinical trial that has completed, run by Abbott RDx Cardiometabolic. The registered enrollment target is 355 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445809 has completed, sponsored by Abbott RDx Cardiometabolic.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test their plasma for a biomarker called NGAL and compare the NGAL levels to their creatinine levels. We hypothesize that NGAL is an earlier marker for kidney injury than creatinine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-04 |
What the finished NCT00445809 record still lists
NCT00445809 is an observational study that tracks outcomes without assigning an intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00445809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00445809 about?
NCT00445809 is a clinical study titled "Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury". Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test the...
What is the current status of trial NCT00445809?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2007-02. Estimated completion is 2009-04.
Who is sponsoring clinical trial NCT00445809?
This trial is sponsored by Abbott RDx Cardiometabolic, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia